Literature DB >> 6819199

Reversible bone-marrow suppression primarily involving granulopoiesis following the use of Ticlopidine.

D Quaglino, L Venturoni, G Cretara, M Ricciotti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6819199

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  3 in total

1.  Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality.

Authors:  F L Paradiso-Hardy; C M Angelo; K L Lanctôt; E A Cohen
Journal:  CMAJ       Date:  2000-11-28       Impact factor: 8.262

Review 2.  Ticlopidine. A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke.

Authors:  S Noble; K L Goa
Journal:  Drugs Aging       Date:  1996-03       Impact factor: 3.923

Review 3.  Adverse haematological effects of ticlopidine. Prevention, recognition and management.

Authors:  B B Love; J Biller; M Gent
Journal:  Drug Saf       Date:  1998-08       Impact factor: 5.606
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.